DoD Gulf War Illness, Research Advancement Award | W81XWH 21 GWIRP RAA

Opportunity Information: Apply for W81XWH 21 GWIRP RAA

The FY21 DoD Gulf War Illness Research Program (GWIRP) Research Advancement Award is a discretionary Department of Defense funding opportunity designed to push Gulf War Illness (GWI) research further along the applied, translational path, specifically within the "Qualification" phase of the program's research pipeline. The intent is not to start from scratch, but to build on credible signals that already exist in the GWI field by expanding, replicating, and validating promising biomarkers, mechanistic targets, and therapeutic approaches. Proposals are expected to be grounded in preliminary data, with a clear and testable hypothesis supported by existing evidence, and with a strong line of sight to real-world benefit for Veterans.

A central requirement of this award is impact. Applications have to explain, in plain and explicit terms, how the project will move the field toward clinical impact for Veterans with GWI, even if the project itself does not immediately deliver a clinical product or a completed human study. The focus must remain on Gulf War Veterans from the 1990-1991 deployment era who are affected by GWI, and the work should address recognizable features of the illness rather than general fatigue or nonspecific multi-symptom conditions. In practice, reviewers are looking for projects that reduce uncertainty around what is biologically happening in GWI and that sharpen the path toward diagnostics, patient stratification, or treatment development.

The program supports two broad categories of activity. First, it funds efforts that expand limited but compelling datasets on candidate markers, mechanistic targets, therapeutics, or other interventions relevant to GWI. Second, it supports replication and development work that makes a therapeutic concept more "actionable," such as confirming druggable targets, advancing leading compounds, or generating preclinical evidence needed either to repurpose an already approved drug or to support a new Investigational New Drug (IND) application to the FDA. If an applicant wants to test an FDA-approved drug in an animal model, they are expected to justify why animal efficacy testing is still necessary before moving into a clinical pilot in humans, rather than using animal studies as a routine step.

While applicants can propose studies across the GWI mission space, the FY21 announcement highlights several areas of emphasis. There is particular interest in replication and validation of treatments that have already shown positive effects, along with fast-tracking newer, credible directions in GWI biology that appear ready for translation. A major theme is understanding and targeting dysregulated biological system function tied to common and debilitating symptom clusters, including cognitive problems (memory deficits and mood/behavior disturbances), non-restorative sleep, chronic widespread pain, severe fatigue, gastrointestinal problems (such as dietary intolerances, GERD, and functional GI disorders), sinus and respiratory effects, headaches, dermatological issues, neurological dysfunction across central/peripheral/autonomic/neuromuscular domains, immune dysfunction, and endocrine/exocrine/excretory disruptions with notable attention to kidney and liver processes (including cytochrome P450 abnormalities). The announcement also calls out interest in microbiome variation, symptom flares triggered by stressors like exertion or immune challenge, and "system crosstalk" where dysfunction in one system drives problems in others (for example, immune changes affecting the nervous system, or autonomic dysfunction disrupting GI function).

Beyond symptom-focused biology, the award encourages projects that identify molecular signatures underpinning GWI, including genomic, proteomic, metabolic, and epigenetic signals, and that use those signatures to group symptom sets into subtypes with shared pathobiology. The opportunity also supports work on comorbidities, mortality, sex-based or ethnic differences, and whether GWI changes outcomes of other infections or diseases. Another stated priority is treatments and biomarkers tailored to specific GWI subtypes, reflecting an interest in moving away from one-size-fits-all approaches and toward better patient stratification.

A notable feature of this funding mechanism is the optional Biorepository Contribution Option tied to the Boston Biorepository, Recruitment, and Integrative Network (BBRAIN) for GWI. Because the program has invested in infrastructure to retain and distribute Gulf War Veteran biospecimens and associated data, applicants are encouraged to contribute biospecimens and/or data to BBRAIN. Proposals that meet the requirements for this option may qualify for a slightly higher direct cost limit, but they must follow additional submission instructions, including a specific biorepository contribution statement.

The announcement is also clear about what it will not fund. It does not support deriving GWI diagnostic biomarkers solely from animal models, reflecting the expectation that diagnostic claims need direct relevance to Veterans. It discourages animal trials of FDA-approved drugs when there is already sufficient evidence to justify moving straight to human testing. It will not support studies that treat psychiatric disease or psychological stress as the primary cause of GWI, and it excludes ALS-focused applications (though Gulf War Veterans with ALS may be included if ALS is part of the study's GWI case definition and the focus remains on GWI symptomatology). Importantly, it does not fund clinical trials as defined by prospective assignment of human subjects to interventions to evaluate outcomes; investigators wanting to run a clinical trial are directed instead to other GWIRP mechanisms such as the Clinical Evaluation Award or the Therapeutic/Biomarker Trial Award.

From an administrative standpoint, awards are made as assistance agreements, meaning they will be issued as either grants or cooperative agreements depending on how much "substantial involvement" the DoD anticipates during the project (for example, collaboration or participation in the research). The expected direct cost cap for the full period of performance is $600,000, or $620,000 if using the Biorepository Contribution Option. The DoD anticipated allocating about $1.92 million total to make roughly two awards under this mechanism, with actual funding dependent on federal availability and the scientific/programmatic strength of submissions. The opportunity (W81XWH-21-GWIRP-RAA; CFDA 12.420) was open broadly to eligible entities, was posted in March 2021 with an August 19, 2021 closing date, and planned to make awards no later than September 30, 2022, using FY21 funds available for obligation through September 30, 2027.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Gulf War Illness, Research Advancement Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Mar 11, 2021.
• Applicants must submit their applications by Aug 19, 2021. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 2 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 21 GWIRP RAA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: